Navigation Links
Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
Date:5/15/2008

APPENZELL, Switzerland, May 15 /PRNewswire/ -- Ergonex Pharma today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to Terguride for the treatment of pulmonary arterial hypertension (PAH). Terguride is currently being evaluated for PAH in a pivotal Phase II trial in Europe.

"The FDA's grant of orphan drug designation to Terguride for PAH encourages and strengthens our development program by offering regulatory, clinical development and commercial benefits," said Dr Rudolf Reiter, CEO of Ergonex Pharma. "We believe that Terguride can provide a significant therapeutic benefit in PAH by inhibiting excess serotonin signalling."

The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases, which affect 200.000 persons or less in the United States. Under the Orphan Drug Act, upon marketing authorization, the FDA does not accept or approve other applications to market the same medicinal product for the same indication for a seven-year period. In addition to potential market exclusivity, orphan drug designation provides protocol assistance, advice on the conduct of clinical trials, tax credits for clinical research expenses, grant funding for research of rare disease treatments and waiver of the Prescription Drug User Fee Act filing fee.

About Terguride

Terguride has strong anti-serotoninergic activity by acting as a potent antagonist on 5-HT2B and 5-HT2A receptors: It has anti-proliferative and anti-fibrotic activity and drives reverse remodelling processes. Serotonin is a signal molecule in the body with many functions. In the blood vessel walls of the lung it stimulates proliferation of smooth muscle cells and narrowing of the blood vessels, which leads to PAH. Excessive proliferative effects of serotonin on the heart contribute directly to progression towards heart failure.

Terguride is cli
'/>"/>

SOURCE Ergonex Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)..., CAMBRIDGE, Mass., Jan. 6 Cequ...of novel products to deliver RNAi-based treatments...t the company has recently completed a successful ...y administered tk RNAi therapeutic targeting the ...milial adenomatous polyposis). FAP is an inherited...
(Date:1/6/2009)..., PARIS, France, January 6 /PRNewswire-Firs...t to Extend the Collaboration Until,December 2011...ation to Include Antibody,Discovery in Ophthalmol...ts to ExonHit if Allergan,Sublicenses to a Third ...ALEHT) today announced a reinforcement,of its exi...
(Date:1/5/2009)..., BETHESDA, Md., Jan. 5 /PRNewswire-FirstCa...rmaceutical company developing novel, proprietary,...ion and autoimmune diseases,provides an outlook ..., Micromet intends to provide an update on its...ng events: , -- April 12 to 16, 2009: Updat...
(Date:1/3/2009)..., , , , , ROSEMONT, Ill., J...e imaging (MRI) is a growing technology providing ...d in the evaluation of back pain according to an a... the American Academy of Orthopaedic Surgeons ( ht...the next several years, additional technical devel...
Breaking Medicine Technology:Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid tolerant Patients with Non cancer Breakthrough Pain 40 1Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid tolerant Patients with Non cancer Breakthrough Pain 40 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid tolerant Patients with Non cancer Breakthrough Pain 40 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid tolerant Patients with Non cancer Breakthrough Pain 40 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid tolerant Patients with Non cancer Breakthrough Pain 40 5H2Diesel Completes 3 Million Gallon Per Year Pilot Facility 35 1H2Diesel Completes 3 Million Gallon Per Year Pilot Facility 35 2H2Diesel Completes 3 Million Gallon Per Year Pilot Facility 35 3Dynavax Issued Landmark Patent Covering Second Generation TLR9 Agonists 30 1Dynavax Issued Landmark Patent Covering Second Generation TLR9 Agonists 30 2Benitec MOU With CalbaTech Inc 25 1Benitec MOU With CalbaTech Inc 25 2Benitec MOU With CalbaTech Inc 25 3Benitec MOU With CalbaTech Inc 25 4
...isrepresented Prescription Pain,Reliever to Health... 2007-The U.S. Food and Drug,Administration,s (FDA...d today that The Purdue Frederick Company, Inc. ha...criminal charges and civil,liabilities in connecti... and sell OxyContin, a powerful prescription pain ...
...pped to Meet Pace of Innovations and a Health Cons...ire-USNewswire/ -- The Food,and Drug Administratio... in the history of healthcare, Commissioner Andrew...g Law Institute,s 50th,Annual Conference April 12 ...g" ways to use its limited,financial and personnel...
Other Medicine Technology:FDA Announces Results of Investigation Into Illegal Promotion of,OxyContin by The Purdue Frederick Company, Inc. 2FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations,FDA Regulations 2
(Date:1/8/2009)...OCKVILLE, Md., Jan. 8 A...es, advice and guidance on drugs, biological produ...care Research and Quality,s Centers for Education ...sponsored network of more than a dozen leading res...Health Advisory Information Network ( CHAIN ) htt...
(Date:1/8/2009)...RAZER, Pa., Jan. 8 Ceph... Frank Baldino, Jr., Ph.D., Chairman and CEO will ... to be held on January 13, 2009 in San Francisco, ... Eastern Time). The presentation will be webcast l...ny,s website. , , The webcast will be archived...
(Date:1/8/2009)...ompany,s Email Encryption business continues to dr...ewswire-FirstCall/ -- Zix Corporation (ZixCorp(R))... for email encryption and e-prescribing, today off...icer, Rick Spurr. , , "We ended the year on a h...ooked the highest orders for the year in the fourt...
(Date:1/8/2009)...ew magnetically-navigated guidewire provides minim...ase , , AUSTIN, Texas, Jan. 8 ...l in the world to use the new Stereotaxis RF Power...t chronic total occlusions (CTOs), or complete blo... , , Austin Heart interventional cardiologist, ...
Breaking Medicine News(10 mins):Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 3Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 2Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 3Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 4Health News:Heart Hospital of Austin First in World to Use New Device for Blocked Arteries 2
...the report of a medical charity in the UK it is fo...e Patients and healthcare officials. //The Governm... patient-friendly health services through the curr...hind Australia, Canada, New Zealand, Germany and t...
...rmy has banned chronic snorers from joining up. Th... the Army. //"Given that chronic snorers' sounds d...s been added," the Beijing Times newspaper quoted ... People's Liberation Army is the world's strongest...
...dore surgically removed an arrowhead, which was em... weapon was removed surgically the tribal// belong...s if nothing has happened. Gajuram, 35, of Khargo...ow by fellow tribesman Kaliya when he refused to g...
...h is to conduct a weeklong education campaign, sta...to school, in the form of rallies, art exhibitions...ucation centre) will start an `Education For All W...ng all in the five to 14 years' age group to schoo...
Other Medicine News:
...to be a proven, reliable penile implant. Recent st...ity rates of over 97.5% at five years on first-tim...nt mechanical reliability rates for the Alpha I. T...d girth expansion to fill the corpora.,Is proven t...
...an advanced three-part inflatable prosthesis consi...ump placed in the scrotum and a pair of cylinders ...mulates the look and performance of a natural erec...ant technology, the AMS 700 Series now features th...
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort.
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort.
Medicine Products: